§HealingResearch protocol
LL-37.
LL-37 (also known as CAP-18) is a 37-amino-acid cationic antimicrobial peptide derived from the C-terminal of human cathelicidin (hCAP18)[1]. It is the only known human cathelicidin, exhibiting bro...
Research Use Only. PeptiJournal supports private research documentation and calculation support. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.
Cited diluent3 mL
Cited protocol example—review and confirm.
Reference syringe capacity
Concentration
1,666.667
mcg/mL
Per event
50 mcg
7 events/week
Vials projected
3
8 cited weeks
Calculated volume reference
3.0 units
1mL syringe
LL-37
3.0u(0.030 mL)
Daily
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Week 1
50 µg
Units / volume3 units (0.03 mL)
Week 2
100 µg
Units / volume6 units (0.06 mL)
Week 3
150 µg
Units / volume9 units (0.09 mL)
Week 4
200 µg
Units / volume12 units (0.12 mL)
Week 5
250 µg
Units / volume15 units (0.15 mL)
Week 6
300 µg
Units / volume18 units (0.18 mL)
Week 7
350 µg
Units / volume21 units (0.21 mL)
Week 8
400 µg
Units / volume24 units (0.24 mL)
| Phase | Daily reference amount | Units / volume |
|---|---|---|
| Week 1 | 50 µg | 3 units (0.03 mL) |
| Week 2 | 100 µg | 6 units (0.06 mL) |
| Week 3 | 150 µg | 9 units (0.09 mL) |
| Week 4 | 200 µg | 12 units (0.12 mL) |
| Week 5 | 250 µg | 15 units (0.15 mL) |
| Week 6 | 300 µg | 18 units (0.18 mL) |
| Week 7 | 350 µg | 21 units (0.21 mL) |
| Week 8 | 400 µg | 24 units (0.24 mL) |
Cited guide source: View source